Nuffield Department of Population Health, University of Oxford, Oxford, UK; Guy's and St Thomas' NHS Foundation Trust, Department of Medical Physics, London, UK.
Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Radiother Oncol. 2020 Dec;153:155-162. doi: 10.1016/j.radonc.2020.08.022. Epub 2020 Sep 3.
Radiation-related heart disease (RRHD) can occur many decades after thoracic radiotherapy for Hodgkin lymphoma (HL) or childhood cancer (CC). To quantify the likely risk of RRHD for patients treated today, dose-response relationships derived from patients treated in previous decades are used. Publications presenting these dose-response relationships usually include estimates of uncertainties in the risks but ignore the effect of uncertainties in the reconstructed cardiac doses.
MATERIALS/METHODS: We assessed the systematic and random uncertainties in the reconstructed doses for published dose-response relationships for RRHD risk in survivors of HL or CC. Using the same reconstruction methods as were used in the original publications, we reconstructed mean heart doses and, wherever possible, mean left-ventricular doses for an independent case-series of test patients. These patients had known, CT-based, cardiac doses which were compared with the reconstructed doses to estimate the magnitude of the uncertainties and their effect on the dose-response relationships.
For all five reconstruction methods the relationship between reconstructed and CT-based doses was linear. For all but the simplest reconstruction method, the dose uncertainties were moderate, the effect of the systematic uncertainty on the dose-response relationships was less than 10%, and the effects of random uncertainty were small except at the highest doses.
These results increase confidence in the published dose-response relationships for the risk of RRHD in HL and CC survivors. This may encourage doctors to use these dose-response relationships when estimating individualised risks for patients-an important aspect of personalising radiotherapy treatments today.
霍奇金淋巴瘤(HL)或儿童癌症(CC)接受胸部放射治疗后数十年可能会发生放射性心脏疾病(RRHD)。为了量化当今患者发生 RRHD 的可能风险,使用了从数十年前接受治疗的患者中得出的剂量-反应关系。发表这些剂量-反应关系的出版物通常包括风险不确定性的估计,但忽略了重建心脏剂量不确定性的影响。
材料/方法:我们评估了 HL 或 CC 幸存者 RRHD 风险的已发表剂量-反应关系中重建剂量的系统和随机不确定性。使用与原始出版物中相同的重建方法,我们为独立的测试患者系列重建了平均心脏剂量,并且在可能的情况下重建了平均左心室剂量。这些患者具有已知的基于 CT 的心脏剂量,并将其与重建剂量进行比较,以估计不确定性的大小及其对剂量-反应关系的影响。
对于所有五种重建方法,重建剂量与 CT 剂量之间的关系都是线性的。除了最简单的重建方法外,所有方法的剂量不确定性都适中,系统不确定性对剂量-反应关系的影响小于 10%,并且随机不确定性的影响很小,除非在最高剂量下。
这些结果增强了对 HL 和 CC 幸存者 RRHD 风险的已发表剂量-反应关系的信心。这可能会鼓励医生在估计患者的个体化风险时使用这些剂量-反应关系,这是当今个性化放射治疗的一个重要方面。